Skip to main content

Advertisement

Fig. 2 | Journal of Translational Medicine

Fig. 2

From: The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort

Fig. 2

Performance of TIS assay vs other biomarkers in NSCLC cohort. a Boxplot of TIS scores in responders and non-responders in the NSCLC cohort. All patients were treated with nivolumab. The response was fit to TIS scores with logistic regression and p-value = 0.033, indicating that high TIS scores are predictive of tumor response to anti PD-1 treatment. The odds ratio is 3.27, 95% confidence interval (1.23, 11.63). b The Kaplan–Meier curves of TIS score groups for the NSCLC cohort. Patients are stratified by TIS score tertiles, and the highest TIS score group was observed to have longer survival than the other two groups (which are combined into the “low” group on the graph). The survival time is fit to TIS score group (high vs low and intermediate) with Cox proportional hazard model. Hazard ratio is 0.36, 95% confidence interval (0.14, 0.90), p-value = 0.0235, meaning the high TIS score group has a decrease of the hazard by 64%. c The Kaplan–Meier curves of NSCLC patients with 1% PD-L1 positivity on tumor cells used as a cutoff. The survival time in the NSCLC cohort is fit to PD-L1+ group (high vs low) with Cox proportional hazard model. d The Kaplan–Meier curves of NSCLC patients with 50% PD-L1 positivity on tumor cells used as a cutoff. The survival time in the NSCLC cohort is fit to PD-L1+ group (high vs low) with Cox proportional hazard model. Analysis suggests that patients with 50% PD-L1+ tumor cells may have longer survival, but the sample size is too limited to reach statistical significance. e The Spearman correlation matrix between TIS scores, percentage of PD-L1+ tumor cells, tumor mutation burden and tobacco exposure for NSCLC cohort. PD-L1+ tumor cells and TMB are positively correlated with tobacco exposure

Back to article page